ETER100: what clinicians are saying
benmelstobart plus anlotinib in first-line advanced renal cell carcinoma · NCT04523272 ↗ · Phase 3 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
A speaker in the discussion reads ETER100 favorably because its results resemble existing combinations, yet would forgo PD-L1 inhibition if PD-1 agents were available. They speculate that the low complete-response rate could reflect a class-activity difference, without comparative proof. An unverified account separately suggests a change in treatment positioning—a different emphasis, not a documented direct debate. The speaker describes overall survival as immature at the time, not as showing an absence of survival benefit.
Created with AI · how we check it
- edition 1
- commentary checked Nov 22, 2026
- 44 verified statements
4 findings, and what sits behind each
01. ETER100: a speaker likens it to options but avoids PD-L1 with PD-1 access
No named clinician · accounts and unnamed speakers · 8 statements in 1 source, a podcast or video · 1 passage
Limitations recorded: 4.
Draws on: The comparison, Design and conduct, Primary endpoint: Progression free survival (PFS) evaluated by Independent Review Committee(IRC), Population and setting.
02. ETER100: what a speaker highlights in the PFS benefit versus Sunitinib
No named clinician · accounts and unnamed speakers · 11 statements from 1 speaker in 4 sources, 1 of them a podcast or video · 7 passages
Limitations recorded: 4.
Draws on: The comparison, Primary endpoint: Progression free survival (PFS) evaluated by Independent Review Committee(IRC), Design and conduct, Secondary endpoints, Population and setting.
03. ETER100 tolerability: what a speaker relays from the presentation
No named clinician · accounts and unnamed speakers · 15 statements from 1 speaker in 3 sources · 13 passages
Limitations recorded: 4.
Draws on: Safety and tolerability.
Beyond the trial population
04. Advanced RCC: how a speaker tailors care with extreme cross-trial caution
No named clinician · accounts and unnamed speakers · 5 statements from 1 speaker in 1 source · 4 passages
Limitations recorded: 3.
Counts overlap, since one statement can back several findings. They show what the report kept, not how many clinicians agree. The full report includes the interpretations and source links.
Select a finding to see what the full report holds for it. Select a part of the trial to see which findings draw on it.
- Finding 1 of 4
No named clinician · accounts and unnamed speakers
ETER100: a speaker likens it to options but avoids PD-L1 with PD-1 access
8 statements in 1 source, a podcast or video
No named speaker is counted in this finding: its title's view comes from speakers the source does not name
- 8
- statements
- 1
- passage
- 1
- source
- 0
- speakers
What the statements areViews 3Questions and uncertainty 1Clinical experience 0Comparisons 4Restated results and context 0Statement-to-passage links (a passage can back several statements)Supporting a statement 8Giving context 1Recorded with the findingLimitations: 4
1 podcast or video
Draws on: The comparison, Design and conduct, Primary endpoint: Progression free survival (PFS) evaluated by Independent Review Committee(IRC), Population and setting.
- Beyond the trial population
Thicker lines mean more shared statements. A finding without a line goes beyond the registered design. Counts overlap: one statement can back several findings.
1 of the 4 findings and 5 of the 44 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.
Abbreviations (7)
HCP, healthcare professional; IRC, independent review committee; MCP, Model Context Protocol, how AI agents read the report; NPI, National Provider Identifier, the US registry number for clinicians; PD-L1, programmed death-ligand 1; PFS, progression-free survival; RCC, renal cell carcinoma.
The full ETER100 report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified statements, each linked to the original. One report in the catalog, IDeate-Lung01, is free in full, so you can see what a paid report holds before you buy: read the free IDeate-Lung01 report.
By the numbers
- 24commentary sources screened
- 6sources cited by verified statements
- 3named in screened sources
- 2speakers cited in the report
- 2cited speakers with a verified identity
0 cited clinicians, speakers with a confirmed clinical role, of them 0 physicians.
Also in the sources: 1 organizational or shared account, not counted as people.
- 44verified statements, each linked to its source
- 0of them from speakers with a confirmed clinical role
- 4findings
Built by AI from public clinician commentary, checked by automated review; every statement links to its source.
A cited clinician is a cited speaker whose clinical role the NPI registry or their own institution's staff page confirms; a role a source only states is not counted. A verified identity says who a speaker is, with or without such a role. Physicians are clinicians whose confirmed role is a physician's.
Counts show what the report kept, not how many clinicians hold a view. Size is set by the verified statements; Standard and Deep need 5 or more cited clinicians. Statements from sponsors, hosts and organisations are labelled and count apart.
What's inside
| Section | Items | Access |
|---|---|---|
| Findings with interpretation, counterviews and limits | 4 | Titles free |
| Detailed analysis | 6 sections | Paid |
| Verified statements with short source quotes and links | 44 | Paid |
| Who said each statement: the cited speakers | 2 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 0 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 2 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 8 | Free |
| Sources with links | 6 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |
Every edition names who said each statement, with MCP access for your AI agent. Each verified speaker comes with their verified IDs (NPI, ORCID, staff page) so your team can check each attribution. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
Trial aspects
8 discussed · 0 no commentary found · 0 assessment incomplete| Aspect | Statements | Sources |
|---|---|---|
| Primary endpoint: Progression free survival (PFS) evaluated by Independent Review Committee(IRC) | 4 | 3 |
| Secondary endpoints | 1 | 1 |
| Population and setting | 1 | 1 |
| The comparisonThe registered arms and what clinicians said about how they compare. | 7 | 3 |
| Safety and tolerability | 1 | 1 |
| Design and conduct | 2 | 1 |
| Overall response, complete response and checkpoint-class activity | 4 | 2 |
| Cross-trial interpretation and patient-centered selection in advanced kidney cancer | 5 | 1 |
Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.
Sources
44 verified statements from 6 cited sources. A video or podcast is one source but often carries many statements, so the table counts statements, not just posts.
| Channel | Statements | Cited | Screened | |
|---|---|---|---|---|
| Video & audio · 9 statements · 21% | ||||
| YouTube | 9 | 1 | 1 | |
| Posts · 8 statements · 18% | ||||
| X threads | 8 | 3 | 23 | |
| Primary sources · 27 statements · 61%cited for context, not screened | ||||
| Publications | 27 | 2 | — | |
Screened: found and read for this trial. Cited: backs at least one statement. Bar = statements; a statement drawn from two sources counts half to each. How we sourced and checked this
max 12 / quarter
- Screened window
- Nov 18, 2021 → Nov 21, 2026
- Cited window
- Nov 19, 2021 → Sep 16, 2025
- Retrieved
- Nov 22, 2026
The trial
from ClinicalTrials.gov- Title
- A Randomized, Positive Parallel Controlled, Multicenter Phase III Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer
- Registry
- NCT04523272
- Study IDs
- TQB2450-III-07
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Design
- Phase 3 · Interventional, randomized, parallel
- Status
- Unknown
- Enrollment
- 528 actual
- Registered
- 2020-08-21
- Start
- 2020-08-25 actual
- Primary completion
- 2025-06 estimated
- Primary endpoint
- Progression free survival (PFS) evaluated by Independent Review Committee(IRC)
- Interventions
- 3 registered
More on: Renal cell carcinoma, benmelstobart
Scope and limits
This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.
- Discussion that does not name the trial may be missing from this edition.
- 16 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 25 sources about other trials or topics are not included.
- The substantive commentary summarized here comes from three X threads and one video discussion. These sources cannot establish how common a view is among HCPs, and reposts are not additional independent endorsements.
- Discussion using unnamed trial references, alternative spellings or other terminology may have been missed. Silence on a topic is not evidence that clinicians have no view.
Show all 12 known gaps +Fewer −
- The video speaker cannot be named, and the video's date is not provided. The November 2021, September 2024 and September 2025 posts must not be interpreted as a sequence showing changing opinion.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- The video and the 2021 selection thread do not name ETER100. The former addresses its regimen and comparator; the latter supplies broader advanced-kidney-cancer treatment-selection context rather than trial-specific results commentary.
- The complete-response concern has no numerical rate in the discussion, and the comparisons with other combinations are not head-to-head evidence. The speaker's checkpoint-class explanation remains speculative.
- The linked renal publication supplies practical context, not an independently attributed HCP practice survey. Its post-hoc, single-trial analysis may miss subclinical injury, does not resolve long-term renal outcomes, and does not validate routine use of its proposed monitoring schedule.
- The primary study population was Chinese and concerned first-line advanced clear-cell RCC; extrapolation beyond that setting requires caution.
- No full protocol or exact product labels accompany these sources. Jurisdiction-specific approval, access and prescribing conclusions cannot be drawn.
How reports are built and checked: Methods.
Editions and corrections
Last checked for new commentary Nov 22, 2026 UTC. No changes. Follow new editions and changes in this report's change feed (JSON Feed), or the catalog's. How versions and corrections work.
Cite this report
Erudio Health. ETER100 (NCT04523272): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 22, 2026. https://www.erudio.com/reports/eter100-nct04523272
For your AI agent
Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.
Help me decide whether to buy the Erudio report "ETER100" (NCT04523272), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.
1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "eter100-nct04523272". If you cannot make requests, read https://www.erudio.com/reports/eter100-nct04523272.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email, my organization and the product: the current edition, or 3, 6 or 12 months of updates. Call create_order with report "NCT04523272", that product, email and organization, then show me the quote and the checkout_url to pay by card. If you have a wallet with a payment client for HTTP 402 (MPP with USDC on Tempo, or x402 with USDC on Base) and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id NCT04523272 and sections ["all"], and summarize the findings for me with their sources. The full report can be long: save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.
When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.Or read the record directly: JSON, Markdown or MCP
curl https://www.erudio.com/reports/eter100-nct04523272.json
curl https://www.erudio.com/reports/eter100-nct04523272.md
# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "eter100-nct04523272" })release ea0a93bd4ad84bb661b9e72ce64ba4f876d1bfb42716fb3a87b03adb530e3743
Questions
How much does the ETER100 report cost?
This edition is below our minimum for clinicians and sources, so it is not for sale yet. Contact us if you are still interested.
What does the ETER100 report cover?
44 statements from 6 sources (1 video, 3 posts, 2 papers), each linked to its source. Commentary checked Nov 22, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.
Can my AI agent read or buy the ETER100 report?
Its preview, yes: get_report_card({ "slug": "eter100-nct04523272" }) on https://mcp.erudio.com/free, with no sign-in. It cannot be ordered yet. Connect your AI client.
How current is the ETER100 report?
Edition 1 (version 1.0.0), accepted Nov 22, 2026 UTC; last checked for new commentary Nov 22, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.